Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

ConvaTec Group PLC

Healthcare GB CTEC

245.0GBX
6.60(2.77%)

Last update at 2026-03-10T15:45:00Z

Day Range

241.60245.40
LowHigh

52 Week Range

209.40309.42
LowHigh

Fundamentals

  • Previous Close 238.40
  • Market Cap4721.46M
  • Volume923772
  • P/E Ratio40.37
  • Dividend Yield2.96%
  • EBITDA587.00M
  • Revenue TTM2439.00M
  • Revenue Per Share TTM1.21
  • Gross Profit TTM 1372.00M
  • Diluted EPS TTM0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 234.83M 245.90M 167.40M 81.90M 151.30M
Minority interest - - - - -
Net income 178.67M 190.50M 130.30M 62.90M 117.60M
Selling general administrative - 195.00M 200.40M 214.90M 285.30M
Selling and marketing expenses - 645.20M 610.90M 575.90M 539.70M
Gross profit 1374.24M 1283.60M 1204.20M 1103.90M 1123.10M
Reconciled depreciation - 220.80M 214.80M 209.20M 210.60M
Ebit 415.54M 319.40M 280.10M 207.30M 203.60M
Ebitda 644.24M 540.20M 455.50M 417.60M 405.70M
Depreciation and amortization 228.70M 220.80M 175.40M 210.30M 202.10M
Non operating income net other - - - - -
Operating income 415.54M 324.90M 262.70M 207.30M 203.60M
Other operating expenses 2074.63M 1964.30M 1879.70M 1851.40M 1834.70M
Interest expense 71.47M 73.50M 73.30M 64.70M 44.30M
Tax provision - 56.00M 37.10M 19.00M 33.70M
Interest income - 4.80M 5.20M 5.50M 0.80M
Net interest income - -78.10000M -75.50000M -67.70000M -43.50000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 56.15M 56.00M 37.10M 19.00M 33.70M
Total revenue 2490.17M 2289.20M 2142.40M 2072.50M 2038.30M
Total operating expenses 958.70M 958.70M 941.50M 882.80M 919.50M
Cost of revenue 1115.93M 1005.60M 938.20M 968.60M 915.20M
Total other income expense net -180.71351M -79.00000M -95.30000M -125.40000M -52.30000M
Discontinued operations - - - - -
Net income from continuing ops - 189.90M 130.30M 62.90M 117.60M
Net income applicable to common shares - - - 62.90M 117.60M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3782.38M 3515.00M 3713.70M 3592.00M 3674.00M
Intangible assets 646.24M 805.90M 935.00M 924.90M 902.20M
Earning assets - - - - -
Other current assets 10.00M 78.00M 105.80M 408.60M 338.60M
Total liab 2263.82M 1826.10M 2021.00M 1982.30M 1979.20M
Total stockholder equity 1518.55M 1688.90M 1692.70M 1609.70M 1694.80M
Deferred long term liab - - - - 1.90M
Other current liab 97.04M 301.70M 320.00M 166.20M 62.20M
Common stock 251.09M 251.50M 251.50M 250.70M 247.00M
Capital stock - 251.50M 251.50M 250.70M 247.00M
Retained earnings 1306.48M -828.40000M -888.70000M -892.20000M -842.00000M
Other liab - - - 169.00M 136.50M
Good will 1350.49M 1290.20M 1298.80M 1224.60M 1156.30M
Other assets - - - - 54.40M
Cash 75.03M 64.70M 97.60M 143.80M 463.40M
Cash and equivalents - - - - -
Total current liabilities 616.22M 512.30M 536.40M 533.10M 569.20M
Current deferred revenue - - - - -
Net debt 1537.56M 1136.90M 1214.80M 1156.40M 971.70M
Short term debt 26.01M 22.00M 20.70M 20.30M 164.50M
Short long term debt - - - 0.00000M 144.80M
Short long term debt total 1612.59M 1201.60M 1312.40M 1300.20M 1435.10M
Other stockholder equity 31.01M 2265.80M 180.40M 2251.20M 2289.80M
Property plant equipment - - - 479.80M 450.30M
Total current assets 940.34M 793.30M 870.00M 889.30M 1110.80M
Long term investments - - - - -
Net tangible assets - - - - -363.70000M
Short term investments - - 0.70M - -
Net receivables 439.16M 301.00M 269.80M 364.00M 323.50M
Long term debt - 1122.80M 1226.90M 1211.90M 1199.80M
Inventory 416.15M 349.60M 396.10M 336.90M 308.80M
Accounts payable 493.18M 124.90M 136.90M 346.60M 342.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -70.02550M - 2149.50M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 15.90M 38.50M 46.80M 25.50M
Deferred long term asset charges - - - - -
Non current assets total 2842.03M 2721.70M 2843.70M 2702.70M 2563.20M
Capital lease obligations - 78.80M 85.50M 88.30M 90.50M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -160.80000M -285.70000M -348.30000M -206.50000M
Change to liabilities - - - 40.70M 10.70M
Total cashflows from investing activities -212.36390M -160.80000M -285.70000M -348.30000M -206.50000M
Net borrowings - -98.00000M 9.40M -149.00000M -114.10000M
Total cash from financing activities -263.41292M -263.80000M -124.00000M -237.10000M -199.90000M
Change to operating activities - - - -3.30000M 6.70M
Net income 178.67M 190.50M 130.30M 62.90M 117.60M
Change in cash -3.93881M -32.90000M -46.20000M -319.60000M -102.00000M
Begin period cash flow 78.97M 97.60M 143.80M 463.40M 565.40M
End period cash flow 75.03M 64.70M 97.60M 143.80M 463.40M
Total cash from operating activities 479.86M 396.20M 367.40M 281.70M 305.90M
Issuance of capital stock - - - - -
Depreciation 228.70M 220.80M 214.80M 209.20M 210.60M
Other cashflows from investing activities - 2.70M 0.60M - -
Dividends paid 142.94M 130.20M 110.70M 88.10M 85.80M
Change to inventory -38.79725M 27.50M -49.40000M -36.30000M -19.60000M
Change to account receivables -59.21686M -26.90000M 18.70M -63.60000M -29.40000M
Sale purchase of stock -332.83958M -10.90000M 0.00000M - 0.00000M
Other cashflows from financing activities -46.96509M -24.70000M -22.70000M 693.50M 469.80M
Change to netincome - - - 72.10M 9.30M
Capital expenditures 137.83M 122.10M 129.20M 144.20M 94.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -33.69235M 3.30M -6.10000M -62.50000M -31.60000M
Stock based compensation - 19.80M 14.60M 16.70M 16.40M
Other non cash items 137.83M -38.20000M 13.80M 55.40M 48.00M
Free cash flow 342.03M 274.10M 238.20M 137.50M 211.80M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CTEC
ConvaTec Group PLC		 6.60 2.77% 245.00 40.37 16.18 1.94 4.09 3.14 14.84
AMS
Advanced Medical Solutions Group plc		 6.70 3.44% 201.50 50.25 17.86 1.97 1.78 2.36 13.12
TSTL
Tristel		 8.00 2.11% 388.00 51.11 37.04 6.08 7.11 5.94 27.03
SPEC
Inspecs Group plc		 -0.075 0.09% 82.92 - 12.29 0.42 0.80 0.60 9.42
BVC
Batm Advanced Communications Ltd		 0.45 3.07% 15.10 - - 0.45 0.71 0.45 11.26

Reports Covered

Stock Research & News

View All

Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for used in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

ConvaTec Group PLC

20 Eastbourne Terrace, London, United Kingdom, W2 6LG

Key Executives

Name Title Year Born
Mr. Karim Bitar CEO & Director 1965
Mr. Jonathan P. Mason Group CFO & Director 1964
Mr. Donal Balfe Exec. VP and Chief of Quality & Operations NA
Dr. Divakar Ramakrishnan Ph.D. Exec. VP & Chief Technology Officer NA
Mr. Mark Reynolds Director of Investor Relations NA
Ms. Kate Postans VP of Investor Relations & Corp. Communications NA
Ms. Natalia Kozmina Exec. VP & Chief HR Officer NA
Mr. Christian Hoengaard Sr. VP & GM - USA NA
Ms. Kjersti Grimsrud Biotechnology, M.Sc. Pres & COO of Infusion Care 1961
Mr. Supratim Bose Pres & COO of Global Emerging Markets 1952

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.